News

NEWS RELEASE

Pivot Park and Spinnovation Analytical join forces to provide analytical solutions at Pivot Park Life Sciences Community, Oss

11 March 2013: Spinnovation Analytical BV, Nijmegen, The Netherlands: Spinnovation Analytical B.V. and Pivot Park have entered into an agreement where Spinnovation will supply analytical services at the newly established life sciences park, while gaining access to Pivot Park’s advanced analytical platform.

NEWS RELEASE

Fastest Spent Media Analysis Validated against ICH Guidelines

Spinnovation Biologics' Spedia-NMR^TM Meets Stringent Pharma Guidelines

19 November 2012: Spinnovation, Nijmegen, The Netherlands: The increasingly popular cell culture analysis and optimization method, Spedia-NMR™ from Spinnovation Biologics, has now been validated internally in accordance to industry guidelines for analytical procedures issued by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).

NEWS RELEASE

Spinnovation Biologics Predicts Biomanufacturing Success

18 April 2012: Spinnovation Biologics, Nijmegen, The Netherlands: With expertise and know-how in high-end analysis for biologics, Spinnovation Biologics today announces the launch of a breakthrough solution – Spedia-Predict™ – for Bioprocess performance troubleshooting and performance prediction of bioproduction, at the annual Bioprocess International European meeting.

TALK ANNOUNCEMENT

Achieving BioManufacturing Success

Are you tackling the issue of biomanufacturing consistency? Attempting to get to the root causes and find solutions for cell culture performance variability in large-scale commercial production? Are you confident about how your cell media will perform?

If you are currently involved in addressing these issues, you'll already recognise that current technologies for characterising complex cell culture media are lacking. Good Manufacturing Practice (GMP) and FDA Quality by Design (QbD) approaches demand close control, but traditional analytical methodology are costly, time consuming and require sample preparation ahead of measurement. Crucially, they also lack the ability to characterize chemically complex media.

Frederic Girard, Spinnovation-Analytical's CEO will be announcing a new service to enable biomanufacturing consistency, for chemically-defined and complex media, at this week's annual Bioprocess International™ European meeting. Catch him on Wednesday, 18th April, 2012 at the Clarion Congress Hotel, Prague.

Can't make it? This e-mail address is being protected from spambots. You need JavaScript enabled to view it for the presentation PDF, or better still, give us a call.

NEWS RELEASE

Spinnovation Biologics Beats Targets

24 February 2012: Spinnovation Biologics, Nijmegen, The Netherlands: Echoing a trend in the growth of biologics and biosimilars market, technology provider Spinnovation Biologics has tripled its client base over the past twelve months. This growth has come from within biotech and pharma industries focused on the research, development and manufacture of biologics products, and has led to an increased demand for the company's Spedia-NMR^TM spent media service. The success has allowed the company to expand into the US bioprocess and biologics markets, with its first permanent business development presence in Pennsylvania.

NEWS RELEASE

Spinnovation expands into the US

24 January 2012: Spinnovation, Nijmegen, The Netherlands: Spinnovation announces that it further anchors its presence in the US market through the collaboration with Quantum Tessera in Collegeville, Pennsylvania.This exciting extension to the business came after the Company trebled the number of clients in the biotech and pharma markets last year. Internationally renowned specialist in the field of biologics, Dr Edward Zartler from Quantum Tessera, will be working with Spinnovation to develop biologic and biosimilar characterisation markets in the US.

NEWS RELEASE

Spinnovation Biologics Spedia-NMR^TM Gains Momentum in Client Adoption

13 December 2011: Spinnovation, Nijmegen, The Netherlands: Increasing demand for Spedia-NMR™ technology from Spinnovation Biologics is expected to continue. This analytical service proves its value in providing fast, fine-tuning of cell culture feeding strategy, delivering improved cell viability and higher product yield. Unique to Spinnovation Biologics - the new division of Spinnovation Analytical BV (Nijmegen, The Netherlands) - Spedia-NMR™ has shown itself to be faster and more reproducible than liquid chromatography (LC)-based methods for cell culture media analysis.

NEWS RELEASE

Spinnovation Introduces An Approach To Improve Biologicals Manufacturing Processes At BioProduction conference

12 October 2011: Spinnovation, Nijmegen, The Netherlands: Addressing the issue of improving methods for optimizing the bioprocessing of biologics, Dr Frederic Girard, CEO of NMR services specialist Spinnovation, will present a talk at 'BioProduction' in Berlin, Germany, on 19-20 October.

NEWS RELEASE

Spinnovation points stem cell culture in the right direction

05 October 2011: Spinnovation, Nijmegen, The Netherlands: Spinnovation, the NMR profiling experts, have produced a detailed case study examining the utility of NMR profiling methodology to monitor and optimise stem cell culture media, for the production of biologics and cells for therapeutic purpose. For more information please visit http://bit.ly/SPIcasestudy

NEWS RELEASE

Spinnovation Biologics Offers Service Choices To Meet individual Analysis Needs For Bioprocess Optimization

30 August 2011: Spinnovation, Nijmegen, The Netherlands: As demand increases for better ways to develop, control and manufacture biologics and biosimilars, Spinnovation Biologics has developed three different options for accessing its services for biologics production: Pay per Sample, Contract Analysis and Custom Services. All are designed to provide clients with the most efficient and appropriate access to Spinnovation Biologics' fast (from 5 working days), detailed and cost-effective bioanalysis services, according to their own specific requirements.